According to Perrigo's latest financial reports the company's current revenue (TTM) is $4.65 B. In 2022 the company made a revenue of $4.45 B an increase over the years 2021 revenue that were of $4.13 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $4.65 B | 4.58% |
2022 | $4.45 B | 7.56% |
2021 | $4.13 B | -4.3% |
2020 | $4.32 B | -10.6% |
2019 | $4.83 B | 2.23% |
2018 | $4.73 B | -4.34% |
2017 | $4.94 B | -1.99% |
2016 | $5.04 B | -5.67% |
2015 | $5.35 B | 28.25% |
2014 | $4.17 B | 9.8% |
2013 | $3.79 B | 16.45% |
2012 | $3.26 B | 10.24% |
2011 | $2.95 B | 17.64% |
2010 | $2.51 B | 18.4% |
2009 | $2.12 B | 6.42% |
2008 | $1.99 B | 28.42% |
2007 | $1.55 B | 11.2% |
2006 | $1.39 B | 14.23% |
2005 | $1.22 B | 32.65% |
2004 | $0.92 B | 9.27% |
2003 | $0.84 B | 2.83% |
2002 | $0.82 B | 0.89% |
2001 | $0.81 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
United Therapeutics UTHR | $2.32 B | -50.01% | ๐บ๐ธ USA |
Endo International
ENDPQ | $2.01 B | -56.79% | ๐ฎ๐ช Ireland |
Intercept Pharmaceuticals
ICPT | $0.31 B | -93.18% | ๐บ๐ธ USA |
Catalent CTLT | $4.09 B | -11.98% | ๐บ๐ธ USA |